# New antifungals targeting the synthesis of fungal sphingolipids

> **NIH NIH R01** · STATE UNIVERSITY NEW YORK STONY BROOK · 2021 · $782,800

## Abstract

ABSTRACT
 The ultimate goal of this proposal renewal entitled, “New antifungals targeting the synthesis of fungal sphingolipids”, is
to continue the optimization of our 3rd generation compounds that we generated using the previous funding cycle, with the
ultimate goal to subject 1-5 compounds at the end of the renewal to preclinical studies and file an Investigational New Drug
(IND) with the Food Drug Administration (FDA) for the treatment of invasive fungal infections (IFI). IFIs are increasingly
responsible for serious life-threatening conditions, particularly in individuals with compromised immunity. For the past 10 years,
we have been working on the research and development of a new class of antifungal agents directed against the synthesis of
fungal but not mammalian sphingolipids. The initial discovery of N’-(3-bromo-6-hydroxybenzylidene)-2-methylbenzohydrazide
(BHBM) as the hit compound from library screening lead us to initiate an intensive research program involving the
combinatorial/parallel synthesis of BHBM derivatives and the assessment of a structure-activity relationship. This program
allowed us to synthesize a 3rd-generation compounds more efficacious than the antifungals currently used in the clinic.
 Our 3rd-generation compounds have secured intellectual property (IP) and a start-up company (MicroRid Technologies
Inc.) with licensing options was co-funded, bringing the necessary expertise to further develop these potent antifungal
compounds. We now seek to optimize pharmacokinetics, toxicology properties without losing antifungal activity. We initiated
the synthesis of several hundred compounds to create a 3rd generation compounds based on D13 (Aim 1) that will be assessed
for antifungal activity and mechanism of action (Aim 2). A few selected compounds will be subjected to toxicology and intensive
PK studies (Aim 3), and, finally, one compound will ultimately be selected for IND filing. Our experience, expertise, and ongoing
effort in this area of antifungal research and the partnership between Stony Brook University, the Long Island High Tech
Incubator, and MicroRid Technologies Inc. place us in a very unique position to achieve these goals.

## Key facts

- **NIH application ID:** 10070688
- **Project number:** 2R01AI116420-06
- **Recipient organization:** STATE UNIVERSITY NEW YORK STONY BROOK
- **Principal Investigator:** Maurizio Del Poeta
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $782,800
- **Award type:** 2
- **Project period:** 2015-12-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10070688

## Citation

> US National Institutes of Health, RePORTER application 10070688, New antifungals targeting the synthesis of fungal sphingolipids (2R01AI116420-06). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10070688. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*